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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.043Alterations in the microtubule (MT)eassociated protein, tau, have emerged as a pivotal phenomenon in
several neurodegenerative disorders, including frontotemporal dementia and Alzheimer’s disease. Although
compelling lines of evidence from various experimental models suggest that hyperphosphorylation and
conformational changes of tau can cause its aggregation into ﬁlaments, the actual tau species and effective
mechanisms that conspire to trigger the degeneration of human neurons remain obscure. Herein, we
explored whether human embryonic stem cellederived neural stem cells can be exploited to study conse-
quences of an overexpression of 2N4R tau (two normal N-terminal and four MT-binding domains; n-tau)
versus pseudohyperphosphorylated tau (p-tau) directly in human neurons. Given the involvement of tau in
MT integrity and cellular homeostasis, we focused on the effects of both tau variants on subcellular transport
and neuronal survival. Byusing inducible lentiviral overexpression,we show thatp-tau, butnot n-tau, readily
leads to an MC-1epositive protein conformation and impaired mitochondrial transport. Although these
alterations do not induce cell death under standard culture conditions, p-taueexpressing neurons cultured
under noneredox-protected conditions undergo degeneration with formation of axonal varicosities
sequestering transported proteins and progressive neuronal cell death. Our data support a causative link
between the phosphorylation and conformational state of tau, microtubuli-based transport, and the
vulnerability of human neurons to oxidative stress. They further depict human embryonic stem cellederived
neurons as a useful experimental model for studying tau-associated cellular alterations in an authentic
human system. (Am J Pathol 2013, 182: 1769e1779; http://dx.doi.org/10.1016/j.ajpath.2013.01.043)Supported by the German Federal Ministry for Education and Research
BioPharma-NeuroAllianz grant 1615608A, the SCR&Tox consortium
under the FP7-HEALTH-2010-Alternative-Testing-Strategies of the Euro-
pean Union project 266753, and the Hertie Foundation (all to O.B.).
Disclosures: O.B. is a cofounder and has stock in Life&Brain GmbH.
Current address of J.M., Laboratory of Genetics, The Salk Institute for
Biological Studies, La Jolla, California.Tauopathies, including Alzheimer disease and certain forms
of frontotemporal dementia, are a class of neurodegenerative
disorders characterized by hyperphosphorylation, patho-
logical conformation, accumulation, and aggregation of the
microtubule (MT)eassociated protein, tau. Tau is naturally
restricted to neurons; its best-established role is to promote
binding and stabilization of MT along the axons.1 By
modulating MT dynamics, tau is considered to regulate
axonal transport of several cellular components, including
signaling molecules or organelles, and to modulate and
stabilize neuronal morphological characteristics.2
Alternative splicing of three exons of tau leads to the
expression of six different isoforms in humans. During
development, these isoforms are differentially expressed
with expression of only the shortest isoform (lacking
both N-terminal domains and containing only three of the
four microtubuli-binding domains) in early development
and all six isoforms in the adult central nervous system.stigative Pathology.
.Structurally, the longest adult tau isoform contains two N-
terminal domains (2N) and four MT-binding domains (4R).
MT binding of tau is regulated by post-translational modi-
ﬁcation, such as phosphorylation (the tau protein has as many
as 84 putative phosphorylation sites), with phosphorylation
negatively regulating the binding to MT.3 Under pathological
conditions, hyperphosphorylated tau disengages from the
MT and tends to self-associate and accumulate into patho-
logical paired helical ﬁlament structures, which can eventually
lead to aggregate and ﬁbril formation.4,5 Although results
from various in vitro and in vivo studies directly link
Mertens et alhyperphosphorylated, misfolded, or aggregated tau to
neuronal loss, the exact species and the prevalent mechanisms
that act together in tau-induced neurodegeneration, especially
in the human system, remain elusive.6,7 Considering the
limited access to vital human brain tissue, most studies were
restricted to transgenic mice, drosophila, transformed cell
lines, or human post-mortem specimens. Herein, we set out to
explore whether in vitro differentiated human embryonic stem
cells (hESCs) can serve as amodel system for studying the role
of tau in the homeostasis of human neurons. As a ﬁrst step
toward modeling pathological mechanisms underlying tauo-
pathies in this in vitro system, we report on the impact of
a misfolded MC-1epositive pseudohyperphosphorylated tau
variant on MT-based mitochondrial transport and neuronal
survival.
Materials and Methods
Neural Stem Cell Culture and Differentiation
Generation of long-term self-renewing neuroepithelial stem
cells (lt-NES cells) from hESCs (originally derived from
line I3) was performed as previously described.8 The lt-NES
cell lines were previously generated from the hESC lines
H9.2 and I3, which were provided by Joseph Itskovitz-Eldor
(Technion, Israel Institute of Technology, Haifa, Israel). The
lt-NES cells were cultured on polyornithine/laminin-coated
dishes in Dulbecco’s modiﬁed Eagle’s/F12 media contain-
ing N2 supplement (1:100), 10 ng/mL ﬁbroblast growth
factor 2, 10 ng/mL epidermal growth factor (EGF), 1:1,000
B27 supplement, and 0.8 mg/L glucose. Neuronal differ-
entiation was initiated on Matrigel-coated dishes by omis-
sion of growth factors in redox-protected media [1:1 (v/v)
mixture of Dulbecco’s modiﬁed Eagle’s/F12 and Neuro-
basal media supplemented with 300 ng/mL cAMP, 1:200
N2 supplement, and 1:100 B27 supplement].
Culture and Treatment of Human Neurons
Neuronal cultures were replated on Matrigel-coated plastic
dishes after 4 weeks of differentiation. Redox-protected
medium was supplemented with 1:100 B27 that contains
the antioxidants sodium pyruvate, thioctic acid, D,L-a-
tocopherol, D,L-a-tocopherol-acetate, catalase, glutathione,
and superoxide dismutase. Noneredox-protected medium
(Dulbecco’s modiﬁed Eagle’s/F12 media supplemented with
1:100 N2) contains no antioxidative supplements. Treatment
with 5 nmol/L okadaic acid (OA;Merck, Darmstadt, Germany)
for 48 hours and 200 mmol/L pyocyanine (Enzo, Farmingdale,
NY) for 1 hour was performed in parallel with appropriate
solvent controls.
Live Cell Analysis of Mitochondrial Transport
Mitochondria were stained by culturing cells in the presence
of 1:20,000MitoTracker RedCM-H2XRos (InvitrogeneLife
Technologies, Carlsbad, CA) for 30 minutes, and live-cell1770recording was performed at 37C in 5% CO2 using an
Observer.Z1 microscope equipped with an external HXP120
lamp, AxioCam MRm/c, TempModule-S, and CO2 Module-
S (Carl Zeiss, Jena, Germany). Images were taken every 10
seconds and processed using ImageJ software version 1.42q
(NIH, Bethesda, MD). Mitochondria were monitored in
individual neuronal processes. Box-plot diagrams were
generated using GraphPad Prism software version 5.0
(GraphPad, LaJolla, CA). Kymographs were generated using
the MultipleKymograph plug-in for ImageJ.
Vector Design and Lentiviral Transduction
For conditional overexpression, the Lenti-X Tet-On Advanced
System (Clontech, Mountain View, CA) was modiﬁed by
replacing the cytomegalovirus promoter of the pLVX-Tet-On
plasmidwith the elongation factor 1 (EF1)a promoter, resulting
in the pLVX-EtO vector. The coding DNA sequences for
enhanced green ﬂuorescent protein (EGFP), human 2N4R tau
(n-tau), and the pseudo-hyperphosphorylated variant [p-tau; 10
serine and threonine residues substituted with glutamic acid;
a kind gift from Prof. Roland Brandt (University of Osna-
brück, Germany)] were ampliﬁed by PCR and cloned into the
pLVX-Tight-Puro vector, resulting in pLVXTP-n-tau and
pLVXTP-p-tau. Production of lentiviral particles was per-
formed as previously described.9 Brieﬂy, HEK-293FT cells
were cotransfected with the packaging plasmid psPAX2, the
envelope plasmid pMD2.G, and the respective lentiviral vector
plasmid. Viral particles were enriched by centrifugation. The
lt-NES cells (I3) were transduced with pLVXTP-EtO and the
respective pLVXTP vector and passaged in the presence of
200 mg/mL G418 (PAA, Pasching, Austria) and 1 mg/mL
puromycin (Sigma-Aldrich, Munich, Germany). Nonover-
expressing control cells were transduced with the pLVXTP-
EtO vector only.
Immunoblotting
Cells were scraped from the dishes and incubated in radio-
immunoprecipitation assay buffer (Sigma-Aldrich), for 1 hour at
4C, containing protease inhibitors (Roche cOmplete ULTRA;
Roche, Basel, Switzerland) and phosphatase inhibitors (Roche
PhosSTOP; Roche). Lysates were clariﬁed by centrifugation at
16,000  g for 15 minutes at 4C, and immunoblotting was
performed following standard procedures. For Western blot
analysis, proteins were separated by SDS-PAGE and subse-
quently blotted on a polyvinylidene diﬂuoride membrane. For
dot blot analysis, cell lysates were directly blotted on nitrocel-
lulose membranes. The membranes were blocked with 10%
Roti-Block (Carl Roth, Karlsruhe, Germany) in Tris-buffered
saline with Tween 20 and detected using appropriate anti-
bodies (Table 1). Horseradish peroxidaseecoupled secondary
antibodies (Thermo Scientiﬁc, Schwerte, Germany) and Su-
perSignal West Chemiluminescent Substrates (Thermo Scien-
tiﬁc) were used for visualization. For dephosphorylation, lysates
(radioimmunoprecipitation assay buffer containing proteaseajp.amjpathol.org - The American Journal of Pathology
Table 1 Antibodies Used in This Study
Antibody Epitope Source Dilution Species
5A6 Pan-t DSHB 1:250 ms
Actin Actin Millipore 1:2000 ms
Activated caspase-3 Activated caspase-3 Promega 1:200 ms
4G8 APP Millipore 1:1000 ms
AT100 Phospho-t S212/S214 Thermo Scientific 1:100 ms
AT8 Phospho-t S202/T205 Thermo Scientific 1:500 ms
b-III Tubulin b-III Tubulin Millipore 1:1500 ms
b-III Tubulin b-III Tubulin Millipore 1:2000 rb
CP9 pt T231 Gift from Dr. Peter Davies 1:250 ms
DACH1 Dachshund homolog 1 ProteinTech 1:50 rb
EGFP EGFP/GFP Abcam 1:3000 rb
FLAG-tag FLAG-tag InvitrogeneLife Technologies 1:800 ms
FLAG-tag FLAG-tag Abgent 1:200 rb
GABA g-Aminobutyric acid Sigma-Aldrich 1:800 rb
Ho14 Human neurofilament Gift from Dr. Virginia Lee 1:100 rat
Kinesin KIF1C Antibodies-Online 1:200 rb
MC-1 t (Conformational epitope) Gift from Dr. Peter Davies 1:10 ms
MC-6 Phospho-t S235 Gift from Dr. Peter Davies 1:250 ms
Nestin Human Nestin R&D Systems 1:800 ms
PHF1 Phospho-t S296/S404 Gift from Dr. Virginia Lee 1:500 ms
PLZF Promyelocytic leukemia zinc finger protein Calbiochem 1:50 ms
SOX2 SRY-box 2 R&D Systems 1:200 ms
t1 Pan-t Millipore 1:500 ms
TG5 Pan-t Gift from Dr. Peter Davies 1:200 ms
ZO1 Tight junction protein 1 Zymed 1:100 rb
ms, mouse; rb, rabbit.
Tau-Induced Toxicity in Human Neuronsinhibitors) were boiled (10 minutes; 95C) and incubated with
lambda phosphatase (New England Biolabs, Ipswich, MA) at
37C for 3 hours before electrophoresis.
Immunoﬂuorescence Analysis
Cells were ﬁxed in 4% paraformaldehyde for 20 minutes at
room temperature, washed in PBS, and blocked with 10%
fetal calf serum in the presence of 0.1% Triton X-100 in PBS.
The respective primary antibodies were applied overnight at
4C (Table 1). Secondary antibodies (Cy3-/FITC-linked goat-
anti-rabbit/mouse/rat; 1:250; Jackson/Dianova, Hamburg,
Germany) were applied for 2 hours at room temperature, and
cell nuclei were counterstained with DAPI (Sigma-Aldrich).
Flow Cytometric Analysis
Cells carrying inducible EGFP were treated with 3 mg/mL
doxycycline for 72 hours, trypsinized, and analyzed using
an FACSCalibur Cytometer (BD Biosciences, San Jose,
CA) for green ﬂuorescence.
Measurement of Total Intracellular Tau and
Phosphorylated Tau at T181 by ELISA
After 4 weeks of differentiation, neurons were treated with
3 mg/mL doxycycline for 3 days and lysed in radioim-
munoprecipitation assay buffer (Sigma-Aldrich). Total
levels of intracellular tau (total and phosphorylated tau atThe American Journal of Pathology - ajp.amjpathol.orgT181) were quantiﬁed by a sandwich immunoassay using
the Innotest hTAU enzyme-linked immunosorbent assay
(ELISA) kit, according to the manufacturer’s instructions
(Innogenetics, Hannover, Germany); this kit contains the
antibodies AT120, AT270, HT7, and BT2.
RT-PCR Analysis
Total RNA from cells was puriﬁed using the RNeasy kit
(Qiagen, Hilden, Germany), and cDNAs were generated
using the iScript cDNA synthesis kit (Biorad, Munich,
Germany). Semiquantitative RT-PCR was performed using
TaqDNA Polymerase (InvitrogeneLife Technologies).
cDNA from RNA extracts of human fetal or adult brains
(Agilent, San Diego, CA) was used as a positive control.
Primers are listed in Table 2.
Determination of Total Cellular ATP, ROS, and
Superoxide
Cultures were differentiated into neurons for 4 weeks and
replated on Matrigel-coated 96-well plates. Cells were
cultured and treated as indicated for the respective experi-
mental setups. For determination of cellular ATP content,
the luminescent CellTiter-Glo kit (Promega, Fitchburg, WI)
was used according to the manufacturer’s instructions.
For measuring total cellular levels of reactive oxygen
species (ROS) and superoxide, the commercial Total ROS/1771
Table 2 PCR Primers Used in This Study
Name Forward primer Reverse primer
Tau exon 3þ 50-CACTGAGGACGGATCTGAGGAACCG-30 50-CACGTGACCAGCAGCTTCGTCTTCC-30
Tau exon 10þ 50-GGGAGCCCAAGAAGGTGGCAGTGG-30 50-CCTTTGAGCCACACTTGGACTGG-30
GAPDH 50-CTGCTTTTAACTCTGGTAAAGT-30 50-GCGCCAGCATCGCCCCA-30
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Mertens et alSuperoxide detection kit (ENZO) was used according to the
manufacturer’s instructions. Recording of luminescence,
red, and green ﬂuorescence signals was performed using
a plate reader (Tecan Group Ltd, San Jose, CA).
Cell Vitality Assay for the Assessment of Survival in
NoneRedox-Protected Medium
The 4-week-old differentiated cultures were replated on
Matrigel-coated, 96-well plates. After treatment with hyd-
rogen peroxide at different concentrations for 24 hours,
alamarBlue staining was performed using the commercial
alamarBlue kit (InvitrogeneLife Technologies) and quan-
tiﬁed using a plate reader (Tecan Group Ltd).
Statistical Analysis
Quantitative data were generated in triplicate or hexaplicate.
Means and SDs were computed using Microsoft EXCEL
2008 and GraphPad Prism software. All results show
means  SD. A Student’s t-test was performed to determine
whether a signiﬁcant difference exists between groups.
Results
Maturation-Dependent Expression and Post-
Translational Modiﬁcation of Tau in hESC-Derived
Neurons
To study expression and post-translational changes of tau in
human neurons, we used our hESC-based lt-NES cells,
a neural stem cell population that can be stably propagated in
culture (Figure 1A8). When omitting the growth factors,
these cells differentiate into approximately 75% to 85% b-III
tubulin-expressing neurons within 4 weeks. Neuronal
cultures typically form complex networks, with axonal
processes extending across several millimeters. Phosphory-
lation of tau at S396/S404 and S212/S214 was detected by
week 4 with the antibodies PHF1 and AT100, respectively,
and increased until week 6 (Figure 1B). This was conﬁrmed
by immunoblot analysis, in which b-III tubulin was detected
in 2-weeks differentiated cultures and further increased by 4
to 6 weeks. By 4 weeks, neurons also expressed tau (5A6:
pan-tau) that was endogenously phosphorylated (PHF1).
Tau levels further increased during neuronal maturation
(Figure 1C). Advanced neuronal differentiation was asso-
ciated with an increased expression of tau mRNA containing
the alternatively spliced exons 3 and 10 (Figure 1D), as well
as the detection of several separately migrating tau protein1772variants that may likely include adult 2N and 4R isoforms
(Figure 1E). Because a dynamic equilibrium of tau
phosphorylation is believed to be crucial for its functional
regulation, we tested whether the phosphorylation pattern
of tau can be modiﬁed. Dephosphorylation by lambda
phosphatase treatment resulted in lower-migrating tau
with increased reactivity to tau antibodies that preferen-
tially recognize unphosphorylated tau (Tau1 and 5A6)
and decreased reactivity to PHF1 (Figure 1F). To test
whether tau phosphorylation can be increased in living
neurons, cultures were treated with the phosphatase
inhibitor OA. Phosphatase inhibition induced a slight
overphosphorylation of tau at several epitopes (AT8,
S202/T205; CP9, T231; MC6, S235; and PHF1) distrib-
uted across different tau species (Figure 1G). Quantiﬁ-
cation of the signals revealed a total phosphorylation
increase of 1.5 to 2.0 fold (Figure 1H). These data indi-
cate the following: i) hESC-derived neurons express
different tau isoforms, including adult variants found in
the human brain; ii) human tau becomes endogenously
phosphorylated to a moderate extent; and iii) human tau is
amenable to overphosphorylation.Conditional Overexpression of n-Tau and p-Tau Results
in Pathological Conformational Changes Only of p-Tau
in Human Neurons
Hyperphosphorylation of tau appears to be the pivotal event in
tauopathies. However, modeling hyperphosphorylation by
phosphatase blockade with OA proved to be inefﬁcient and
highly toxic at longer incubation times (data not shown) and
resulted in broad and unspeciﬁc protein overphosphorylation.
An alternative approach for mimicking hyperphosphorylation
of tau at speciﬁc phosphorylation sites is the use of pseudo-
hyperphosphorylated variants, where serine/threonine sites are
substituted with glutamic acid.7,10 We chose to overexpress
a pseudohyperphosphorylated 2N4R variant of tau (p-tau;
carries 10 pseudohyperphosphorylation sites) (Figure 2A10)
and normal 2N4R tau (n-tau) using an inducible lentiviral
system. This synthetic phospho-tau variant, p-tau, was shown to
exhibit diminished ability to nucleate MT and decreased ﬁla-
ment formation compared with normal tau, thereby mimicking
properties of disease-related and soluble hyperphosphorylated
tau. In other cellular models, such as PC12 and NT2 cells,
overexpression of p-tau resulted in apoptosis and toxicity.10
We ﬁrst generated lt-NES cell lines expressing
advanced reverse tetracycline-controlled transactivator and
the coding sequences for FLAG-tagged n-tau or p-tauajp.amjpathol.org - The American Journal of Pathology
Figure 1 Expression and phosphorylation of tau in maturating hESC-derived neurons. A: Experimental design: Progressive differentiation of lt-NES cells was
monitored over 6 weeks. B: Immunoblot for b-III tubulin, 5A6 (pan-tau), and PHF1 during neuronal differentiation. C: Immunoﬂuorescence staining of b-III tubulin
and phosphorylated tau (PHF1, S396/S404; AT100, S212/S214) in differentiating cultures. D: RT-PCR analysis of tau transcripts during differentiation using primers
speciﬁc for the alternatively spliced exons 3 and 10. E: Immunoblot detection of tau isoforms with TG5 (pan-tau). F: Lambda-hosphataseetreated lysates of lt-NES
cellederived neurons (lines H9.2 and I3) stained with 5A6, Tau1, and PHF1. G: Immunoblot analysis of neurons treated with 5 nmol/L PP1/PP2A inhibitor, OA (48
hours). Phospho-tau antibodies: AT8 (S202/T205), CP9 (T231), MC6 (S235), and PHF1. H: Quantiﬁcation of phospho-tau and b-III tubulin signals normalized to
actin after OA treatment. Data show biological replicates or representative results of at least two independent experiments. Scale bars: 100 mm (B). de-phos., de-
phosphorylated; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Tau-Induced Toxicity in Human Neuronsunder the control of the tetracycline response element tight
promoter (Figure 2B). Selected cell lines expressed the
neuroepithelial stem cell markers Nestin, Sox2, DACH1,
PLZF, and, within neural rosettes, apically accentuated
zonula occludens protein 1 (Figure 2C8). After doxycycline
treatment, lt-NES cells homogenously expressed n-tau or p-
tau, as determined by immunoﬂuorescence with an FLAG-
tag antibody (Figure 2D). Fluorescent-activated cell sorter
analysis of simultaneously established tetOn-EGFP lt-NES
cells revealed only marginal leak expression, with inductionThe American Journal of Pathology - ajp.amjpathol.orgefﬁciencies ranging >90% (Figure 2E and Supplemental
Figure S1, A and B).
To investigate the impact of an overload of n-tau or p-tau
on axonal transport and neuronal survival, we differentiated
n-taue and p-taueexpressing lt-NES cells for 4 weeks before
replating them onto freshly coated tissue culture plates.
Replating of the cells allows the investigation of lt-NES
cellederived neurons for longer time periods, because
initial cultures tend to detach after longer cultivation times.
Replated cultures consistently contained 55% to 65% b-III1773
Figure 2 Conditional expression of n-tau and p-tau in hESC-derived neurons leads to the pathological MC-1 conformation of p-tau. A: Schematic
depiction of human 2N4R tau (n-tau). Pseudohyperphosphorylated p-tau was mutated at S198, S199, S202, T231, S235, S396, S404, S409, S413, and
S422 to glutamic acid.10 Epitopes of phospho-tau antibodies are indicated. B: Schematic representation of the doxycycline-inducible lentiviral vector
system. C: Immunoﬂuorescence analysis of the generated lt-NES cell lines using antibodies to Nestin, DACH1, Sox2, PLZF, and zonula occludens protein
1 (ZO1). D: Immunoﬂuorescence analysis for FLAG-tag after 3 mg/mL doxycycline (dox) induction (72 hours). E: Fluorescence-activated cell sorter
analysis of EGFP expression in wild-type cells (gray) and untreated (black) and doxycycline-treated (green) tetOn-EGFP lt-NES cells. F: Differentiated
and replated cells were immunostained for b-III tubulin, GABA, Nestin, and FLAG-tag. G: Immunoblots for pathological MC-1 tau in cells expressing
doxycycline-induced FLAG-tagged n-tau or p-tau. H: Differentiated neurons were replated at single-cell densities on a layer of mouse astrocytes for
3 days, treated with doxycycline (5 days), and immunostained for MC-1. Data shown are representative for at least three independent experiments.
Scale bars: 50 mm. max, maximum.
Mertens et altubulin-positive neurons, many of which expressed the
neurotransmitter GABA.Cultures also contained 35% to 45%
cells expressing Nestin, which likely represent remaining
progenitors or glial cells (Figure 2F8). Immunoﬂuorescence
analysis revealed homogeneous expression of FLAG-tagged
tau variants on doxycycline induction (Figure 2F). Expres-
sion levels of both tau variants were comparable, as demon-
strated by immunoblot (Figure 2G) andELISAmeasurements
that showed strong and similar levels of overexpression
(n-tau, 7.2-fold; p-tau, 6.2-fold) (Supplemental Figure S1C).
Although both tau variants exhibited comparable phos-
phorylation at T181, the PHF1 antibody, as expected, only1774detected phosphorylated n-tau and did not bind to the pseu-
dophosphorylated epitope in p-tau (Supplemental Figure S1,
D and E). More important, and in agreement with earlier
reports, only p-tau, but not n-tau, adopted the pathological
MC-1 conformation, as evident from immunoblots, immu-
nocytochemical staining, and dot-blot analysis (Figure 2, G and
H, and Supplemental Figure S1F). The MC-1 antibody detects
the disease-associated paperclip conformation of tau that was
described as one of the ﬁrst pathological signatures in
tauopathies.3,7,11e13 Thus, in addition to mimicked hyper-
phosphorylation, p-tau also appears to adopt an aberrant protein
conformation.ajp.amjpathol.org - The American Journal of Pathology
Figure 3 p-Tau impairs MT-based transport of mitochondria in the absence of neurotoxicity. A: Experimental design: lt-NES cells were differentiated for
4 weeks and replated. After 3 days of recovery, n-tau and p-tau expression was permanently induced by doxycycline (dotted bars). B: Mean percentages of
b-III tubulin-positive neurons were monitored over 4 weeks. C: Fractions of b-III tubulin neurons after 4 weeks of expression (ie, week 8 of the
experiment). D: Mean percentages of cells positive for activated caspase-3 at week 8. E: Kymographs depicting motility of live-stained mitochondria along
neuronal processes. The inlay on the right shows neurons live stained with a ﬂuorescent mitotracker. F: Box-plot diagram showing relative fractions of
motile mitochondria (migrating a distance of >0.3 mm/second). The bar marks the median; boxes, lower and upper quartiles; and whiskers, absolute
distribution of all measured neuronal processes (n  22 per group). G: Quantiﬁcation of total cellular ATP levels at week 6. Bar graphs show means  SD of
each group. AU, arbitrary unit. *P < 0.05, ***P < 0.001.
Tau-Induced Toxicity in Human Neuronsp-Tau, But Not n-Tau, Impairs the Transport of
Mitochondria in the Absence of Neurotoxicity
To determine whether overexpression of n-tau or p-tau
induces neurotoxicity, we monitored neuronal survival
for >4 weeks in doxycycline-induced cultures (Figure 3,
A and B). Even after 4 weeks of transgene expression (ie,
week 8 of the experiment), no signiﬁcant differences in
the percentage of b-III tubulin-positive neurons were
observed compared with nonoverexpressing controls
(Figure 3, B and C). Consequently, no activation of
cellular apoptosis was found, as assessed by immunoﬂu-
orescence analysis of caspase-3 induction (Figure 3D). We
next investigated the impact of n-tau and p-tau on the MT-
based transport of mitochondria. To that end, we labeled
mitochondria with a ﬂuorescent mitotracker in neurons
differentiated for 6 weeks (2 weeks after transgene
induction) and analyzed their movements in neuronal
processes by live cell imaging. Interestingly, mitochon-
drial transport was clearly impaired in p-taueexpressing
neurons, as illustrated by representative kymographs
(Figure 3E). The relative fraction of motile mitochondria
(migrating a distance of >0.3 mm/second) signiﬁcantly
decreased by 35% in cells overexpressing p-tau, whereasThe American Journal of Pathology - ajp.amjpathol.orgoverexpression of n-tau had no impact on mitochondrial
motility (Figure 3F). Quantiﬁcation of the cellular ATP
content further revealed a small, but signiﬁcant, decrease
in energy turnover in p-taueexpressing cells (Figure 3G).
Thus, only aberrant p-tau, but not n-tau, impairs MT-
based transport of mitochondria in our human neuronal
culture system, although without ultimately triggering
overt signs of neuronal degeneration or cell death.
p-Tau Critically Enhances Neuronal Sensitivity to
Oxidative Stress, Leading to Progressive Axonal
Degeneration and Cell Death
Defective transport of mitochondria in neuronal processes
overexpressing p-tau might critically affect essential cellular
functions. Considering that mitochondria are involved in the
generation and clearance of ROS,14 we asked whether p-taue
expressing cells might have a lower resistance to coping with
oxidative stress. To test this hypothesis, we switched from
redox-protected medium containing the antioxidant B27
supplement to noneredox-protected medium (containing N2
supplement only), 1 week after the initiation of tau expression
(Figure 4A). As a result, basal cellular levels of ROS and
superoxide were signiﬁcantly higher in noneredox-protected1775
Figure 4 Neurons expressing p-tau in noneredox-protected conditions show enhanced sensitivity to ongoing oxidative stress, progressive axonal
degeneration, and neurotoxic damage. A: Experimental design: After differentiation, replating (re-plat.), and doxycycline (dox) induction in redox-protected
medium for 1 week (dotted bar), the culture medium was switched to noneredox-protected medium (striped bars), and the neurons were monitored for
another 3 weeks. B: Quantiﬁcation of MT-based transport of mitochondria. The bar marks the median; boxes, lower and upper quartiles; and whiskers, absolute
distribution of all measured axons (n  15 per group). C: Mean percentages of b-III tubulin-positive neurons over time. D: Fractions of neurons in noneredox-
protected medium at week 8. E: Mean percentages of neurons positive for activated caspase-3. F: Morphological analysis and immunostaining for b-III tubulin
and FLAG-tag at week 8. G: Detailed immunoﬂuorescence analysis of AV-containing neuronal axons in p-tau cultures compared with n-tau cultures. Cells were
stained for b-III tubulin, FLAG-tag, neuroﬁlaments (hNF; HO14 antibody), Tau1, AT100, MC-1, APP (4G8), kinesin, and activated caspase-3. Images show
representative axons of both populations. H: Quantiﬁcation of condensed nuclei. I: Quantiﬁcation of axons containing multiple AVs over time. Scale bars:
50 mm (G); 10 mm (I). All bar graphs show means  SD of each group. *P < 0.05, ***P < 0.001.
Mertens et al
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Tau-Induced Toxicity in Human Neuronsmedium. Furthermore, 200 mmol/L pyocyanine treatment for 1
hour induced signiﬁcantly elevatedROS and superoxide levels
in noneredox-protected medium. In redox-protected medium,
pyocyanine did not increase total ROS levels and induced only
a moderate increase in total superoxide (Supplemental
Figure S2, A and B). Consequently, in noneredox-protected
medium, neurons were found more vulnerable to hydrogen
peroxideeinduced cell death (Supplemental Figure S2C).
As in redox-protected conditions, we observed decreased
mitochondrial transport only in p-taueexpressing neurons in
noneredox-protected medium (Figure 4B and Supplemental
Figure S3, AeC). Neuronal survival was not signiﬁcantly
affected by expression of n-tau compared with control neurons
(52.8% 3.4% versus 48.6% 2.8% byweek 8) (Figure 4, C
and D). In stark contrast, the neuronal fraction in p-taue
expressing cultures progressively decreased in noneredox-
protected conditions, decreasing to 31.2%  5.8% by week 8
(Figure 4, C and D). At the same time, p-taueexpressing
cultures displayed signiﬁcantly more cells positive for acti-
vated caspase-3 (Figure 4E) and condensed nuclei (Figure 4F
and Supplemental Figure S3D). The progressive degeneration
of neurons was further reﬂected by slightly decreasing total
cell numbers in p-tau cultures (Supplemental Figure S3E).
Defects in subcellular transport and reduced neuronal
survival in p-taueexpressing cells were accompanied by
accumulating signs of neuronal degeneration. Immunoﬂuo-
rescence analysis revealed atypical neuronal morphological
characteristics and multiple tau-containing axonal varicosi-
ties (AVs) detected by the FLAG-tag antibody (Figure 4G).
We observed a rapid increase of AVs over time in p-taue
encumbered neurites, with 47.4% of the neurites showing
AVs already 1 week after transgene induction, whereas in
n-tau neurons, AV formation occurred only at late time points
and was less pronounced (Figure 4H and Supplemental
Figure S3, F and G). AVs, typically 3 to 5 mm in diameter,
accumulated along human neuroﬁlament- and b-III tubulin-
positive neurites (Figure 4I). Although most affected axons
showed smooth and continuousMT, 5% to 10% of the neurites
displayed co-accumulation of b-III tubulin within the FLAG-
positive AVs, whereas neuroﬁlaments remained mostly unaf-
fected (Figure 4I). Virtually all AVs were immunoreactive for
several tau species (Tau1, AT100, andMC-1). p-Taueinduced
AVs also contained axonal proteins, such as APP, which is
a pathological characteristic of degenerating neurons, and the
motor protein kinesin that is usually found evenly distributed
within unaffected neurites (Figure 4I and Supplemental
Figure S3H). Thus, in the absence of antioxidant protection,
an overload of pathological p-tau appears to trigger a neuronal
degeneration cascade associated with AVs sequestering
endogenous axonal proteins and, eventually, neuronal death.
Discussion
The results of our work indicate that in vitro differentiated
hESCs represent a suitable experimental system for studying
the effects of altered tau expression directly in humanThe American Journal of Pathology - ajp.amjpathol.orgneurons.11 Speciﬁcally, we show that p-tau, but not n-tau,
inhibits subcellular transport of mitochondria in the absence
of cell death. However, only in the absence of antioxidant
protection of the cultures, p-taueinduced cellular alterations
result in progressive degeneration of human neurons.
Interestingly and similar to the adult human brain, differ-
entiated hESC-derived neurons express several mature tau
variants (including 2N and 4R isoforms), which are endog-
enously phosphorylated and amenable to experimental
overphosphorylation. These ﬁndings are in line with a recent
study reporting increased expression of 4R over three of the
four microtubuli-binding domains tau during neuronal
differentiation of hESCs, along with the expression of all six
tau isoforms in differentiated cultures.15 Together, these data
suggest that hESC-derived neurons provide probably the
most authentic experimental system for studying the effects
of different tau species in a human background. We used this
paradigm to study the impact of an overload of normal 2N4R
tau and a phospho-tau variant. This variant mimics phos-
phorylation at recognition sites for several phospho-tau
antibodies (AT8, PHF1, MC6, and CP9) and was shown to
impair MT assembly, axonal outgrowth, and cell survival in
the absence of aggregation.10 We demonstrate that p-tau, but
not n-tau, adopts the pathological MC-1 conformation, which
was shown to be directly triggered by combined AT8,
AT100, and PHF1 pseudophosphorylation16 and regarded as
the earliest sign of aberrant tau.17 Because the tau variant
used herein does not induce the formation of aggregates and
tangles, it provides an opportunity for studying pathological
effects of tau that are solely the result of hyper-
phosphorylation and/or conformational changes.
Surprisingly, strong and continuous overexpression of
n-tau or MC-1epositive p-tau did not induce neuronal death
in our cultures. This stands in contrast to the results of
previous in vitro studies, in which the same pseudohyper-
phosphorylation variant was expressed in standard PC12
and NT2-N cell lines and in which cellular degeneration,
accompanied by induction of caspase-mediated apoptosis,
was observed.12 Considering that neurons are frequently
considered highly vulnerable, this is an interesting obser-
vation. On the other hand, mature neurons have to be
prepared for lifelong survival and might, thus, feature
effective mechanisms to protect from stress and apoptosis.13
The lack of neuronal death on overexpression of n-tau or
p-tau is in line with a recent study, in which overexpression
of pseudohyperphosphorylated tau in a transgenic mouse
model was shown to induce only mild effects, without
neurodegeneration.18
Despite missing signs of neuronal death, we found that
only p-tau, but not an overload of n-tau, negatively affects
mitochondrial transport. In neurons, tau facilitates nucle-
ation, dynamic stabilization, and proper spacing of MT,
which provide the main cytoskeletal tracks for MT-based
transport.1,19 MT-associated proteins, including tau, have
been found to directly regulate the motor proteins, kinesin
and dynein.20,21 It is, thus, not unexpected that structurally1777
Mertens et alaltered MC-1 tau negatively affects the subcellular transport
of mitochondria.22 However, in contrast to our human
neuronal model, previous cellular models reported decreased
transport of proteins and organelles to the cellular periphery,
already when overexpressing normal 4R tau.23,24 More
important, this effect was attributed to the tau-mediated initial
attachment of motor proteins/cargos to MT that does not
affect the ﬂow of movement itself.25 Consequently, in an
established axonal system, the ﬂow of transport should not be
disturbed by normal tau. Indeed, our ﬁndings show that when
encountering a situation of mature human neurons with
stably established MT tracks, n-tau did not change the frac-
tion of motile mitochondria, whereas p-tau did. Hyper-
phosphorylated tau in a soluble and unpolymerized state was
shown to disassemble already formed MT by sequestering
normal tau and other MT-associated proteins away fromMT,
which may provide a possible explanation for the detrimental
effect of p-tau on MT-based transport in our system.26e28
Together, these observations support the notion that, in
particular, hyperphosphorylated MC-1 tau can alter MT
functions and compromise mitochondrial transport.
Active intracellular transport of proteins and organelles,
such as mitochondria along MT, is crucial for cellular orga-
nization, function, and the local energy supply within
neurons.29,30 Mitochondria also account for most ROS
production and detoxiﬁcation, and increased net production
of ROS is closely associated with neurodegeneration.31e33 It
is, thus, tempting to speculate that the slightly decreased
cellular ATP levels in p-taueexpressing cultures represent an
early sign of defective neuronal energy supply and that the
diminished capacity of p-tau neurons to cope with ongoing
oxidative stress is the result of hampered mitochondrial
transport,34e36 although deﬁcient transport of other cargos
might contribute to the observed pathological changes.
Neuronal cell loss in p-tau cultures was accompanied by
axonal alterations, such as the formation of multiple AVs.
These axonal swellings typically contain axonal vesicles
and mitochondria. They are observed in early stages of
Alzheimer disease in humans and are considered to reﬂect
altered axonal trafﬁcking.35 In p-tau neurons, AVs sequester
tau, cytoskeletal, and motor proteins and APP.27,37 Unlike
acute neuronal cell death, the slowly progressing axonal
dystrophy accompanied by AVs observed in our cultures
indicates the activation of a neuron-speciﬁc death program
with classic neuropathological hallmarks.38
The observed effects of the pseudohyperphosphorylated
tau variant we used most likely represent a pretangle path-
ological characteristic resulting from a gain of function of
soluble p-tau. Other lines of evidence suggest that paired
helical ﬁlaments and, especially, insoluble tau aggregates
possess additional pathological effects that were not
addressed in our experimental model.39
In conclusion, our data demonstrate that even strong and
protracted overexpression of n-tau is not immediately toxic
to human neurons. In contrast, p-tau severely affects MT-
based transport of mitochondria and increases neuronal1778susceptibility to oxidative stress. Mimicking oxidative stress
conditions by omitting protective antioxidants from the cell
culture media resulted in slowly progressing neurotoxicity
that might be directly linked to altered subcellular transport
of mitochondria and/or other cargos.
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